Last Trading Date: New York Feb 9, 2026
- Merck shares fell 3.51% on Monday, Feb. 9, 2026, closing at $117.65 after insider sale filings weighed on sentiment; the stock edged down about 0.28% in after-hours trading as investors digested the disclosures.
- The decline contrasted with broader market strength, as major U.S. indices posted modest gains, highlighting that Merck’s move was largely stock-specific rather than sector- or market-driven.
- Analysts remain cautiously constructive, with several maintaining Buy/Overweight ratings and raising price targets despite softer 2026 guidance, while traders now focus on upcoming FDA decision deadlines and pipeline updates as the next key catalysts.
On Monday, Feb. 9, 2026, Merck & Co., Inc. (NYSE: MRK) shares dipped sharply in response to news of significant insider sales disclosed in regulatory filings, rattling investor sentiment even as broader indices finished mixed. Merck closed the session at $117.65, down 3.51% from the prior day’s finish, marking a clear retreat for the pharmaceutical giant. In after-hours trading, the stock showed only modest movement, slipping slightly further to around $117.32, a fractional drop of roughly 0.28% as traders continued to digest the latest developments.(Yahoo Finance)
The sell-off came after multiple executives, including Executive Vice President and General Counsel Jennifer Zachary, sold large blocks of stock on Feb. 9, collectively drawing attention to insider activity that some market participants viewed as a bearish signal. While such filings don’t automatically indicate a change in corporate fundamentals, they often weigh on sentiment in the near term.(marketbeat)
Investor focus has remained sharp on Merck’s recent earnings and guidance. The company reported fourth-quarter 2025 results that beat analysts’ expectations with non-GAAP EPS of $2.04 on $16.4 billion in revenue, driven by strong oncology and respiratory franchises. However, its 2026 outlook disappointed some on Wall Street, with revenue and earnings guidance below consensus estimates, as Merck outlined headwinds including patent expirations on key legacy products and integration costs from recent acquisitions.(Barron’s)
Analyst reactions ahead of and following the earnings release have been mixed but generally constructive on the long-term prospective. Several brokerages have raised price targets and maintained Buy or Overweight ratings, reflecting confidence in Merck’s pipeline and key growth drivers even as near-term forecasts remain cautious. Notably, Guggenheim lifted its price target on MRK to $140 with a Buy rating, while other analysts from Citigroup and BofA have also incrementally increased targets or reaffirmed positive stances as fundamentals evolve. On aggregate, analyst consensus pricing points to a median target near the current trading levels, with a broad range of upside scenarios depending on product approvals and commercial execution.(marketbeat)
Beyond the numbers, traders were also parsing Merck’s recent regulatory and pipeline news, including progress on novel therapies and expanded patent protections for cornerstone products—a factor some analysts believe could offset revenue declines from generic competition.(seekingalpha)